A checklist for medication compliance and persistence studies using retrospective databases

被引:522
作者
Peterson, Andrew M.
Nau, David P.
Cramer, Joyce A.
Benner, Josh
Gwadry-Sridhar, Femida
Nichol, Michael
机构
[1] Univ Sci Philadelphia, Dept Pharm Practice & Pharm Adm, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Yale Univ, West Haven, CT USA
[4] ValueMed Res LLC, Falls Church, VA USA
[5] McMaster Univ, London, ON, Canada
[6] Univ So Calif, Los Angeles, CA USA
关键词
compliance; guidelines; persistence; retrospective databases; LIPID-LOWERING THERAPY; PHARMACY RECORDS; STATIN THERAPY; ADHERENCE; VALIDATION; TRIALS;
D O I
10.1111/j.1524-4733.2006.00139.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
The increasing number of retrospective database studies related to medication compliance and persistence (C&P), and the inherent variability within each, has created a need for improvement in the quality and consistency of medication C&P research. This article stems from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) efforts to develop a checklist of items that should be either included, or at least considered, when a retrospective database analysis of medication compliance or persistence is undertaken. This consensus document outlines a systematic approach to designing or reviewing retrospective database studies of medication C&P. Included in this article are discussions on data sources, measures of C&P, results reporting, and even conflict of interests. If followed, this checklist should improve the consistency and quality of C&P analyses, which in turn will help providers and payers understand the impact of C&P on health outcomes.
引用
收藏
页码:3 / 12
页数:10
相关论文
共 24 条
  • [1] Conflicts of interest - Science, money, and health
    Alpert, JS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (06) : 635 - 637
  • [2] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    Altman, DG
    Schulz, KF
    Moher, D
    Egger, M
    Davidoff, F
    Elbourne, D
    Gotzsche, PC
    Lang, T
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) : 663 - 694
  • [3] Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy
    Benner, JS
    Pollack, MF
    Smith, TW
    Bullano, MF
    Willey, VJ
    Williams, SA
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (14) : 1468 - 1475
  • [4] Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
    Benner, JS
    Tierce, JC
    Ballantyne, CM
    Prasad, C
    Bullano, MF
    Willey, VJ
    Erbey, J
    Sugano, DS
    [J]. PHARMACOECONOMICS, 2004, 22 (Suppl 3) : 13 - 23
  • [5] Long-term persistence in use of statin therapy in elderly patients
    Benner, JS
    Glynn, RJ
    Mogun, H
    Neumann, PJ
    Weinstein, MC
    Avorn, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04): : 455 - 461
  • [6] Predictors of adherence with antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Collins, SR
    Battleman, DS
    Schwartz, JS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1147 - 1152
  • [7] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [8] The influence of insulin use on glycemic control - How well do adults follow prescriptions for insulin?
    Cramer, JA
    Pugh, MJ
    [J]. DIABETES CARE, 2005, 28 (01) : 78 - 83
  • [9] Results of a naturalistic study of treatment options: Switching atypical antipsychotic drugs or augmenting with valproate
    Cramer, JA
    Sernyak, M
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (06) : 905 - 914
  • [10] Dezii C M, 2001, Manag Care, V10, P42